Celyad

Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.

Celyad's Positive Data And Other News: The Good, Bad And Ugly Of Biopharma

DexCom

Hologic

NuCana

Teladoc

The health care industry has been rallying so far this year on constant testing and COVID-19 vaccine trials.

5 Health Care Stocks to Bet on as Coronavirus Woes Linger

Celyad SA (CYAD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Celyad SA (CYAD) Rating Upgrade to Strong Buy

MONT-SAINT-GUIBERT, Belgium, May  06, 2020  (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced that Dr. Maria Koehler and Mr. Dominic Piscitelli have been appointed as independent members to its Board of Directors, effective as of March 24 and May 6, respectively.

Celyad Appoints Seasoned Industry Executives to Board of Directors

- Company postpones Extraordinary General Meeting from May 5, 2020 to June 8, 2020 - Company postpones Extraordinary General Meeting from May 5, 2020 to June 8, 2020

Celyad to Host Remote 2020 Ordinary General Meeting

Celyad SA (CYAD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Celyad SA (CYAD) a New Buy Stock

Celyad SA (CYAD) CEO Filippo Petti on Q4 2019 Results - Earnings Call Transcript

MONT-SAINT-GUIBERT, Belgium, March  02, 2020  (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced that Stephen Rubino, Ph.D., has been appointed Chief Business Officer. Dr. Rubino has more than 25 years of strong commercial and strategic development experience in the pharmaceutical and biotechnology industry, including 17 years at Novartis. He will serve on the executive leadership team and will lead business and corporate development for Celyad.

Celyad Appoints Stephen Rubino as Chief Business Officer

MONT-SAINT-GUIBERT, Belgium, Jan.  13, 2020  (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced the successful administration of the next-generation, NKG2D-based candidate CYAD-02 to a relapsed/refractory acute myeloid leukemia (r/r AML) patient enrolled in the Phase 1 CYCLE-1 trial.

Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r/r AML and MDS

MONT-SAINT-GUIBERT, Belgium, Nov.  29, 2019  (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced that Filippo Petti, CEO of Celyad, is joining the Celyad Board of Directors and succeeds Celyad co-founder and former CEO Christian Homsy, M.D. who has resigned from Celyad’s Board of Directors.

Celyad Announces Board of Directors Evolution with New Appointment

MONT-SAINT-GUIBERT, Belgium, Nov.  22, 2019  (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced that the Company has received €8.5 million in grants and non-dilutive funding from the Walloon Region of Belgium. These funds will help support the development of the Company’s CAR-T candidates, including CYAD-01 and CYAD-02 for the treatment of relapsed/refractory acute myeloid leukemia, as well as next-generation approaches currently in preclinical development. The funding for technological innovation received on behalf of the Walloon Region was approved by Mr. Willy Borsus, Vice-President of Wallonia, Minister of Economy, Foreign Trade, Research and Innovation, Digital, Agriculture and Territorial Development.

Celyad Receives €8.5 Million in Grants and Non-Dilutive Funding by the Walloon Region

Celyad SA (CYAD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Celyad SA (CYAD) Moves to Buy: Rationale Behind the Upgrade

MONT-SAINT-GUIBERT, Belgium, Nov.  11, 2019  (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced highlights from the company’s NKG2D-based CAR-T clinical candidates for the treatment of metastatic colorectal cancer (mCRC), including its novel, off-the-shelf cell therapy CYAD-101 and alloSHRINK dose-escalation Phase 1 trial. Results were presented at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting, held in Washington D.C. from November 6-10, 2019.

Celyad Highlights Safety and Clinical Activity of CYAD-101, a First-In-Class, Non-Gene Edited Allogeneic CAR-T Therapy for mCRC, from  SITC 34th Annual Meeting

MONT-SAINT-GUIBERT, Belgium, Oct.  02, 2019  (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced that management plans to participate at the following investor conferences in October and November 2019.

Celyad Announces October and November 2019 Investor Conference Schedule

MONT-SAINT-GUIBERT, Belgium, Oct.  02, 2019  (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced that clinical data on the company’s pipeline of candidates will be presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 6-10, 2019, in Washington, D.C.

Celyad to Present Update on mCRC Clinical Program at the 2019 SITC Annual Meeting

MONT-SAINT-GUIBERT, Belgium, Sept.  16, 2019  (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced the closing of a global offering of 2,000,000 ordinary shares comprised of 1,675,000 ordinary shares in the form of American Depositary Shares (“ADSs”) offered in the United States, Canada and certain countries outside of Europe at a price per ADS of $10.00 (the “U.S. offering”), and 325,000 ordinary shares in Europe and certain countries outside of the United States and Canada in a concurrent private placement at a price per share of €9.08 (together with the U.S. offering, the “global offering”). Each ADS represents the right to receive one ordinary share. The gross proceeds to Celyad from the global offering amounted to approximately $20.0 million (approximately €18.2 million), before deducting underwriting discounts and commissions and estimated offering expenses. In connection with the global offering, Celyad has granted the underwriters a 30-day option to purchase up to an additional 300,000 ordinary shares (which may be in the form of ADSs) on the same terms and conditions.

Celyad Announces Closing of $20 Million Global Offering

MONT-SAINT-GUIBERT, Belgium, Sept.  12, 2019  (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced the pricing of a global offering of 2,000,000 ordinary shares, comprised of 1,717,391 ordinary shares in the form of American Depositary Shares (“ADSs”) offered in the United States, Canada and certain countries outside of Europe at a price per ADS of $10.00 (the “U.S. offering”), and 282,609 ordinary shares in Europe and certain countries outside of the United States and Canada in a concurrent private placement at a price per share of €9.08 (together with the U.S. offering, the “global offering”). Each ADS represents the right to receive one ordinary share.  The price per ADS was determined based on an exchange rate of $1.1008 per €1.  The gross proceeds to Celyad from the global offering are expected to be approximately $20.0 million (approximately €18.2 million), before deducting underwriting discounts and commissions and estimated offering expenses.

Celyad Announces Pricing of $20.0 Million Global Offering

MONT-SAINT-GUIBERT, Belgium, Sept.  10, 2019  (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, announced today that it intends to offer and sell, subject to market and other conditions, up to 2,000,000 ordinary shares in a global offering, which is comprised of an offer of ordinary shares in the form of American Depositary Shares (“ADSs”) in the United States, Canada and certain countries outside of Europe (the “U.S. offering”), and an offer of ordinary shares in Europe and certain countries outside of the United States and Canada in a concurrent private placement (the “European private placement” and, together with the U.S. offering, the “global offering”). Investors other than qualified investors under applicable law will not be eligible to participate in the ordinary share private placement. Each ADS offered in the U.S. represents the right to receive one ordinary share.

Celyad Announces Launch of Proposed Global Offering

MONT-SAINT-GUIBERT, Belgium, Sept.  04, 2019  (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced the successful administration of CYAD-01 produced with the OptimAb manufacturing process to a patient enrolled in cohort 3 (300 million cells) of the Phase 1 DEPLETHINK trial.

Celyad Successfully Doses First Patient with CYAD-01 Produced with OptimAb Manufacturing Process

MONT-SAINT-GUIBERT, Belgium, Aug.  29, 2019  (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced that management plans to participate at the following events in September 2019:

Celyad to Participate in Upcoming September 2019 Conferences

Celyad SA (CYAD) CEO Filippo Petti on Q2 2019 - Earnings Call Transcript

MONT-SAINT-GUIBERT, Belgium, Aug.  22, 2019  (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced its consolidated financial results for the first half of 2019 and provided its second quarter business update. The full interim financial report is available on Celyad’s website in the “Investors” section.

Celyad Reports Half Year 2019 Financial Results and Second Quarter Business Highlights

Celyad has been struggling lately, but the selling pressure may be coming to an end soon.

Celyad Sees Hammer Chart Pattern: Time to Buy?

Celyad SA Sees Hammer Chart Pattern: Time to Buy?

Celyad SA (CYAD) CEO Christian Homsy on Q4 2018 Results - Earnings Call Transcript

News for Celyad Stock (CYAD)